Recent developments in the legal battle over the planned $3.3 billion UnitedHealth Group (NYSE: UHG) acquisition of Amedisys (Nasdaq: AMED) have moved the ...

As home health providers increasingly serve people with more complicated and serious conditions, and the push for ...

UnitedHealth Group and Amedisys outlined plans to divest a significant number of home health and hospice locations as they ...

UnitedHealth Group said its motion to dismiss the DOJ lawsuit was moot after the agency cited which regions would be impacted ...

Shares of UnitedHealth (NYSE:UNH) fell 4.6% Monday as concerns mounted over its pending merger with Amedisys (NASDAQ:AMED) following the announcement that the FTC will maintain Biden-era merger rules.

Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Shares of Amedisys, Inc. (NASDAQ:AMED – Get Free Report) have been given a consensus rating of “Hold” by the six research firms that are presently covering the company, Ratings reports. Five ...

Two whistleblowers have adequately alleged that Amedisys Inc. violated the False Claims Act by improperly billing Medicare and other federal health-care programs for home health services, a New York ...

UnitedHealth Group says the Justice Department’s antitrust challenge to its proposed $3.3 billion purchase of Amedisys is wrong on the merits and threatens to deprive consumers of benefits from ...